Swedish Orphan Biovitrum
Engages in the development, marketing, and distribution of orphan products and specialty pharmaceuticals.
Launch date
Employees
Market cap
$13.6b
Enterprise valuation
$15.5b (Public information from Sep 2024)
Share price
SEK328 SOBI.ST
Company register number 556038-9321
Solna kommun Stockholm County (HQ)
Financials
Estimates*
| SEK | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 15.3b | 15.5b | 18.8b | 22.1b | 24.9b | 27.8b | 31.2b |
| % growth | 7 % | 2 % | 21 % | 18 % | 13 % | 12 % | 12 % |
| EBITDA | 6.3b | 5.8b | 6.2b | 7.2b | 9.0b | 10.8b | 12.8b |
| % EBITDA margin | 41 % | 37 % | 33 % | 33 % | 36 % | 39 % | 41 % |
| Profit | 3.2b | 2.7b | 2.6b | 2.4b | 3.2b | 4.9b | 6.7b |
| % profit margin | 21 % | 17 % | 14 % | 11 % | 13 % | 18 % | 21 % |
| EV / revenue | 4.1x | 4.1x | 3.8x | 5.0x | 5.0x | 4.2x | 3.5x |
| EV / EBITDA | 9.9x | 11.1x | 11.5x | 15.2x | 13.8x | 10.9x | 8.7x |
| R&D budget | 1.6b | 2.0b | 2.4b | 2.8b | - | - | - |
| R&D % of revenue | 10 % | 13 % | 13 % | 13 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
N/A | Acquisition | ||
* | N/A | Post IPO Debt | |
* | N/A | SEK3.0b | Post IPO Debt |
| Total Funding | - | ||
Related Content
Recent News about Swedish Orphan Biovitrum
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Swedish Orphan Biovitrum
Edit
ACQUISITION by Swedish Orphan Biovitrum Nov 2009
ACQUISITION by Swedish Orphan Biovitrum Sep 2019
ACQUISITION by Swedish Orphan Biovitrum May 2023